The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Treatment of Choice?
Oct 19, 2005

Would you start treatment at ALL in the following circumstances, and, if so, which med(s) - assuming no genotyping resistance?

Infected beginning of May 2005, Sep. labs showed CD4 of 654 and Viral Load of 261,000.


Response from Dr. Wohl

Personally, assuming these were repeated and found to be similar, I would probably not start therapy just yet. Others, swayed by the high viral load, would.

In such cases, I explain that the risk of a rapid decline in the CD4 cell count increases with higher viral load. Therefore, if I am able to monitor the patient closely and detect precipitous drops in CD4 cell counts early, I feel secure in watching and waiting.

There is no 'right' answer. If the patient was highly motivated, understood the issues involved and felt strongly about starting therapy early given this viral load, I'd agree.

As to what therapy, any of the standard regimens that we are commonly using as first line therapy in persons with lower CD4 cell counts, be it NNRTI or PI based, would be fine.


infection via the eye; long term non-progression
hiv vaccination

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint